US STOCK
IBRX Stock Analysis
US stocks · market data · technical indicators
ImmunityBio, Inc.
IBRXUS stocksQuote delayed 15 min
9/12 上午01:33 updated
$8.18
+0.46+5.89%
Open
$7.80
High
$8.35
Low
$7.80
Volume
781.73萬
IBRX price history
+7.25%Open
7.65
Latest
8.21
High
8.40
Low
7.57
Average
7.97
Advertisement
AI Composite Technical Analysis
BetaFormula: fundamentals (40%) + technical indicators (30%) + market sentiment (30%)
AI Score75
Score range 0–100; a higher score indicates a stronger buy signal
Market Status
BuyCurrent Price$8.175
Target Price$10.219
Change %+5.89%
Institutional
Moderate
Foreign Ownership
Accumulating
Market Heat
Strong
Fundamentals (US)
P/E Ratio
--
ROE
--
P/B Ratio
-8.22x
Dividend Yield
--
Market Insight
The composite score points to a strong buy signal (75/100), with several technical and fundamental indicators in positive territory. Notable price movement today (+5.89%), indicating increased market attention. The target price implies roughly 25.00% upside.
This analysis is for reference only and does not constitute investment advice. Investing carries risk; educational content only.
Financial snapshot
IBRX - ImmunityBio, Inc.
EPS
-0.95USD
Forward EPS
-0.13USD
P/E
--
Forward P/E
-64.54x
P/B
-8.22x
ROE
--
ROA
-30.54%
Operating margin
-120.41%
Profit margin
0.00%
Revenue growth
93.90%
Earnings growth
--
Dividend yield
--
Financial statements
| 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|---|
| Revenue | $51.24M | $44.21M | $38.28M | $32.06M | $26.43M |
| Gross profit | $50.94M | $43.97M | $37.90M | $31.88M | $26.29M |
| Operating income | -$61.70M | -$69.79M | -$64.68M | -$55.63M | -$71.28M |
| Net income | -$230.38M | -$632.78M | -$61.94M | -$67.25M | -$92.56M |
| Basic EPS | -0.22 | -0.62 | -0.06 | -0.07 | -0.10 |
| Diluted EPS | -0.22 | -0.62 | -0.06 | -0.07 | -0.10 |
Estimates vs actuals
Next earnings
2026-11-03
EPS estimate
-0.05
Revenue estimate
$59.23M
Last surprise
-175.00%
| Date | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-11-03 | -0.05 | Not reported | — |
| 2026-08-04 | -0.08 | -0.22 | -175.00% |
| 2026-05-07 | -0.07 | -0.08 | -20.00% |
| 2026-02-23 | -0.10 | -0.06 | +37.93% |
| 2025-11-04 | -0.10 | -0.07 | +30.00% |
| 2025-08-05 | -0.10 | -0.10 | — |
| 2025-05-12 | -0.14 | -0.15 | -7.14% |
| 2025-03-03 | -0.13 | -0.08 | +38.46% |
| 2024-11-12 | -0.18 | -0.12 | +33.33% |
| 2024-08-12 | -0.15 | -0.20 | -33.33% |
| 2024-05-09 | -0.16 | -0.20 | -25.00% |
| 2024-03-19 | -0.18 | -0.38 | -111.11% |
Institutional holders
| Institution | Quarter | Value held | Portfolio weight |
|---|---|---|---|
| STATE STREET CORP | 2026-06-30 | $187.3M | 0.01% |
| TWO SIGMA INVESTMENTS, LP | 2026-06-30 | $97.2M | 0.07% |
| BlackRock Inc. | 2024-06-30 | $72.2M | 0.00% |
| VANGUARD GROUP INC | 2025-12-31 | $64.9M | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC | 2026-06-30 | $9M | 0.01% |
| CITADEL ADVISORS LLC | 2026-06-30 | $1.2M | 0.00% |
13F quarterly filings. Reporting periods differ by institution; value and weight reflect each institution's own latest quarter.
Analyst ratings
Mean target
$12.75
Target range
$12.00 – $15.00
Implied upside
55.96%
Strong buy
1
Buy
3
Hold
0
Sell
0
Strong sell
0
Advertisement